Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A primitive neuroendocrine liver tumour?

View through CrossRef
The aim of the present report is to present a possible primitive case of a neuroendocrine tumour (NET) of the liver. During a routine ultrasound examination, a 51-year-old woman was diagnosed with a lesion in the second segment of the liver, suggestive of a metastasis. A well differentiated neuroendocrine carcinoma (G2, Ki67 = 4.4%) was identified by liver biopsy, positive for chromogranin, synaptophysin and neuron specific enolase. An additional extensive examination aimed at finding the primitive lesion was unsuccessful and PET with 68Gallium revealed a single liver lesion. A left lobectomy was performed, but 15 months later a second liver lesion with the same characteristics as the previous one was observed and was surgically treated, followed by therapy with octreotide LAR 30 mg. A four-year follow-up did not show evidence of a different primitive NET: therefore, while it is improbable that a metastatic G2 primitive tumour would not have presented in the 4-year period, a diagnosis of primitive NET of the liver was made. The paper gives the opportunity of describing an unusual case of a primitive liver neuroendocrine tumour and of presenting the successful treatment of both surgery and cytoreductive pharmacological therapy.
Title: A primitive neuroendocrine liver tumour?
Description:
The aim of the present report is to present a possible primitive case of a neuroendocrine tumour (NET) of the liver.
During a routine ultrasound examination, a 51-year-old woman was diagnosed with a lesion in the second segment of the liver, suggestive of a metastasis.
A well differentiated neuroendocrine carcinoma (G2, Ki67 = 4.
4%) was identified by liver biopsy, positive for chromogranin, synaptophysin and neuron specific enolase.
An additional extensive examination aimed at finding the primitive lesion was unsuccessful and PET with 68Gallium revealed a single liver lesion.
A left lobectomy was performed, but 15 months later a second liver lesion with the same characteristics as the previous one was observed and was surgically treated, followed by therapy with octreotide LAR 30 mg.
A four-year follow-up did not show evidence of a different primitive NET: therefore, while it is improbable that a metastatic G2 primitive tumour would not have presented in the 4-year period, a diagnosis of primitive NET of the liver was made.
The paper gives the opportunity of describing an unusual case of a primitive liver neuroendocrine tumour and of presenting the successful treatment of both surgery and cytoreductive pharmacological therapy.

Related Results

Surgical strategy for neuroendocrine liver metastases
Surgical strategy for neuroendocrine liver metastases
IntroductionThere are no established strategies for the surgical management of neuroendocrine liver metastases. Surgical treatment options include liver resection, liver transplant...
EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms
EMT Molecular Signatures of Pancreatic Neuroendocrine Neoplasms
Neuroendocrine neoplasms (NENs) are relatively rare neoplasms occurring predominantly in the gastrointestinal tract and pancreas. Their heterogeneity poses challenges for diagnosis...
Rare genital system tumours, neuroendocrine neoplasms: case series and literature review
Rare genital system tumours, neuroendocrine neoplasms: case series and literature review
Neuroendocrine neoplasms (NENs) of the female genital tract are rare tumours. They behave more aggressively than other gynaecological cancers. Clinical presentation and treatment a...
Harnessing iNKT cells to improve in situ vaccination for cancer therapy
Harnessing iNKT cells to improve in situ vaccination for cancer therapy
<p>Toll-like receptor (TLR) agonism in combination with the activation of type I NKT (iNKT) cells through systemic administration of their respective agonists has been shown ...
Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation
Abstract 1801: FOXA1, a novel regulator of neuroendocrine differentiation
Abstract Neuroendocrine prostate cancer (NEPC) is a subtype of prostate cancer that is highly aggressive and exhibits a neuroendocrine phenotype, being distinct from...
Neuroendocrine Biomarkers
Neuroendocrine Biomarkers
Neuroendocrine cells are unique because they are found in almost every organ in the body. These cells often resemble other cell types, making it challenging to differentiate them b...
Localization of immunoreactive HIF‐1α and HIF‐2α in neuroendocrine cells of both benign and malignant prostate glands
Localization of immunoreactive HIF‐1α and HIF‐2α in neuroendocrine cells of both benign and malignant prostate glands
AbstractBACKGROUNDHypoxia induces increased tumor growth by promoting angiogenic and glycolytic pathways. Tumors expressing hypoxia‐inducible factor‐1α (HIF‐1α), an important trans...

Back to Top